{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T08:56:01Z","timestamp":1777452961355,"version":"3.51.4"},"reference-count":36,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Therapy"],"published-print":{"date-parts":[[2019,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Sentinel surveillance of transmitted HIV drug resistance (TDR) among recently infected populations within a country was recommended by the World Health Organization from 2004 to 2015.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Serum specimens collected as part of the 2010, 2011 and 2012 National Antenatal Sentinel HIV Prevalence Surveys were used to estimate provincial and national TDR prevalence in South Africa.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Moderate (5\u201315%) levels of transmitted non-nucleoside reverse transcriptase inhibitor (NNRTI) drug class resistance were detected in three of five provinces surveyed in 2010 and 2011 (Eastern Cape, Free State and KwaZulu-Natal). Inclusion of all nine of South Africa's provinces in the 2012 survey enabled calculation of a national TDR point prevalence estimate: TDR to the NNRTI drug class was 5.4% (95% CI 3.7, 7.8%), with K103N and V106M being the most frequently detected mutations. TDR estimates for the nucleoside reverse transcriptase inhibitor (NRTI) drug class were 1.1% (95% CI 0.5, 2.4%) and 0.6% (95% CI 0.1, 1.6%) for protease inhibitors (PI).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These data provide national TDR estimates for South Africa in 2012 and indicate that levels of TDR were low to moderate for the NNRTI drug class and low for NRTIs and PIs in the population surveyed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3851\/imp3294","type":"journal-article","created":{"date-parts":[[2019,2,11]],"date-time":"2019-02-11T06:47:00Z","timestamp":1549867620000},"page":"203-210","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":7,"title":["Provincial and National Prevalence Estimates of Transmitted HIV-1 drug Resistance in South Africa Measured using two WHO-recommended Methods"],"prefix":"10.1177","volume":"24","author":[{"given":"Gillian M","family":"Hunt","sequence":"first","affiliation":[{"name":"Centre for HIV and STIs, National Institute for Communicable Diseases, a division of the National Health Laboratory Service, Johannesburg, South Africa"},{"name":"Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanna","family":"Ledwaba","sequence":"additional","affiliation":[{"name":"Centre for HIV and STIs, National Institute for Communicable Diseases, a division of the National Health Laboratory Service, Johannesburg, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monalisa","family":"Kalimashe","sequence":"additional","affiliation":[{"name":"Centre for HIV and STIs, National Institute for Communicable Diseases, a division of the National Health Laboratory Service, Johannesburg, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Salimo","sequence":"additional","affiliation":[{"name":"Centre for HIV and STIs, National Institute for Communicable Diseases, a division of the National Health Laboratory Service, Johannesburg, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siyabonga","family":"Cibane","sequence":"additional","affiliation":[{"name":"Centre for HIV and STIs, National Institute for Communicable Diseases, a division of the National Health Laboratory Service, Johannesburg, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beverly","family":"Singh","sequence":"additional","affiliation":[{"name":"Centre for HIV and STIs, National Institute for Communicable Diseases, a division of the National Health Laboratory Service, Johannesburg, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian","family":"Puren","sequence":"additional","affiliation":[{"name":"Centre for HIV and STIs, National Institute for Communicable Diseases, a division of the National Health Laboratory Service, Johannesburg, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalie Exner","family":"Dean","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, College of Public Health & Health Professions, University of Florida, Gainesville, FL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynn","family":"Morris","sequence":"additional","affiliation":[{"name":"Centre for HIV and STIs, National Institute for Communicable Diseases, a division of the National Health Laboratory Service, Johannesburg, South Africa"},{"name":"Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael R","family":"Jordan","sequence":"additional","affiliation":[{"name":"Tufts University School of Medicine, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2018,4,1]]},"reference":[{"key":"bibr1-IMP3294","unstructured":"Statistics South Africa. Mid-year population estimates 2017. (Accessed 4 May 2018.) Available from http:\/\/www.statssa.gov.za\/publications\/P0302\/P03022017.pdf"},{"key":"bibr2-IMP3294","unstructured":"Ministry of Health, Department of Health Planning, Department of Health. Annual public health statistics 2012. Pretoria; 2012. (Accessed 14 August 2018.) Available from http:\/\/www.hst.org.za\/publications\/NonHSTPublications\/AnnualHealthStatistics2012_Aug2013.pdf"},{"key":"bibr3-IMP3294","unstructured":"UNAIDS. Global AIDS Update 2016. (Accessed 6 March 2018.) Available from http:\/\/www.unaids.org\/en\/resources\/documents\/2016\/Global-AIDS-update-2016"},{"key":"bibr4-IMP3294","unstructured":"National Department of Health. The South African Antiretroviral Treatment Guidelines 2010. (Accessed 29 August 2010.) Available from http:\/\/apps.who.int\/medicinedocs\/documents\/s19153en\/s19153en.pdf"},{"key":"bibr5-IMP3294","doi-asserted-by":"publisher","DOI":"10.1086\/587109"},{"key":"bibr6-IMP3294","doi-asserted-by":"publisher","DOI":"10.1177\/135965350901400414"},{"key":"bibr7-IMP3294","doi-asserted-by":"publisher","DOI":"10.1086\/648444"},{"key":"bibr8-IMP3294","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3181bc478b"},{"key":"bibr9-IMP3294","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3283333639"},{"key":"bibr10-IMP3294","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32833a097b"},{"key":"bibr11-IMP3294","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0072152"},{"key":"bibr12-IMP3294","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ556"},{"key":"bibr13-IMP3294","unstructured":"World Health Organization. WHO HIV Drug Resistance Report 2012. Geneva: World Health Organization; 2012. (Accessed 14 June 2013.) Available from http:\/\/www.who.int\/hiv\/pub\/drugresistance\/report2012\/en\/"},{"key":"bibr14-IMP3294","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001845"},{"issue":"2","key":"bibr15-IMP3294","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/135965350801302S03","volume":"13","author":"Bennett D.E.","year":"2008","journal-title":"Antivir Ther"},{"key":"bibr16-IMP3294","unstructured":"WHO. WHO global strategy for the surveillance and monitoring of HIV drug resistance 2012. (Accessed 17 April 2013.) Available from http:\/\/apps.who.int\/iris\/bitstream\/10665\/77349\/1\/9789241504768_eng.pdf"},{"issue":"2","key":"bibr17-IMP3294","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1177\/135965350801302S04","volume":"13","author":"Bennett D.E.","year":"2008","journal-title":"Antivir Ther"},{"key":"bibr18-IMP3294","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/135965350801302S10","volume":"13","author":"Myatt M.","year":"2008","journal-title":"Antivir Ther"},{"key":"bibr19-IMP3294","unstructured":"National Department of Health. The 2010 National Antenatal Sentinel HIV & Syphilis Prevalence Survey in South Africa. 2011. (Accessed 2 June 2012.) Available from http:\/\/www.hst.org.za\/publications\/NonHST%20Publications\/hiv_aids_survey.pdf"},{"key":"bibr20-IMP3294","unstructured":"National Department of Health. The 2011 National Antenatal Sentinel HIV & Syphilis Prevalence Survey in South Africa. Pretoria: Department of Health; 2012. (Accessed 5 November 2013.) Available from http:\/\/www.health.gov.za\/index.php\/2014-03-17-09-09-38\/reports\/category\/99-2013re?download=182:national-antenatal-sentinel-hiv-syphilis-prevalence-survey-in-south-africa"},{"key":"bibr21-IMP3294","unstructured":"National Department of Health. The 2012 National Antenatal Sentinel HIV and Herpes Simplex Type-2 Prevalence Survey in South Africa. Pretoria: Department of Health; 2014. (Accessed 18 August 2014.) Available from http:\/\/www.hst.org.za\/publications\/NonHST%20Publications\/ASHIVHerp_Report2014_22May2014.pdf"},{"issue":"2","key":"bibr22-IMP3294","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1177\/135965350801302S09","volume":"13","author":"Pillay V.","year":"2008","journal-title":"Antivir Ther"},{"key":"bibr23-IMP3294","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir1017"},{"key":"bibr24-IMP3294","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2011.0284"},{"key":"bibr25-IMP3294","doi-asserted-by":"publisher","DOI":"10.4172\/2155-6113.1000299"},{"key":"bibr26-IMP3294","doi-asserted-by":"publisher","DOI":"10.4102\/sajhivmed.v13i1.156"},{"key":"bibr27-IMP3294","unstructured":"World Health Organisation. Global HIV drug resistance laboratory network. 2014. (Accessed 18 June 2014.) Available from http:\/\/www.who.int\/hiv\/topics\/drugresistance\/laboratory\/en\/index2.html"},{"key":"bibr28-IMP3294","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0004724"},{"key":"bibr29-IMP3294","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btp134"},{"key":"bibr30-IMP3294","unstructured":"Copyright 1985-2011 StataCorp LP. Stata Statistical Software: Release 12. 2011. College Station, TX: StataCorp LP; 2011"},{"key":"bibr31-IMP3294","unstructured":"World Health Organization. HIV drug resistance surveillance guidance; 2015 update. Geneva, Switzerland 2015. (Accessed 10 March 2017.) Available from http:\/\/www.who.int\/hiv\/pub\/drugresistance\/hiv-drug-resistance-2015-update\/en\/"},{"key":"bibr32-IMP3294","unstructured":"World Health Organization. World Health Organization Global Action Plan on HIV Drug Resistance 2017-2021. 2017. (Accessed 7 November 2017.) Available from http:\/\/www.who.int\/hiv\/topics\/drugresistance\/en\/"},{"key":"bibr33-IMP3294","doi-asserted-by":"publisher","DOI":"10.7448\/IAS.19.1.21140"},{"key":"bibr34-IMP3294","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0067188"},{"key":"bibr35-IMP3294","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw358"},{"key":"bibr36-IMP3294","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/256982"}],"container-title":["Antiviral Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3851\/IMP3294","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.3851\/IMP3294","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3851\/IMP3294","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T12:52:42Z","timestamp":1777380762000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.3851\/IMP3294"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,1]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["10.3851\/IMP3294"],"URL":"https:\/\/doi.org\/10.3851\/imp3294","relation":{},"ISSN":["1359-6535","2040-2058"],"issn-type":[{"value":"1359-6535","type":"print"},{"value":"2040-2058","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,1]]}}}